ENOV (Enovis) Net Profit

Corporate emblem and logo of enovis.com (ENOV)

The share price history of Enovis Corporation (ENOV) clearly demonstrates business expansion through the acquisition of niche developers and partnerships with physicians. A flawless image in the B2B segment ensures customer loyalty, with the current metric standing at -1.10. The company's financial stability relies on the natural aging of the population and the scheduled nature of operations, rendering demand for its products independent of economic crises.

ENOV: Enovis Corporation Net Profit 04/28/2023 - 11/01/2026

Financial and market metric breakdowns for Enovis (ENOV)

- current quotes and average value forecast:
Market Chart Enovis Inc.|ENOV - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Enovis Inc.|ENOV - Total Company Value
- book capitalization data:
Net Assets per Single Share Enovis|ENOV - Book Capitalization|Market Capitalization to Book Value enovis.com|ENOV - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Equity Enovis Corporation|ENOV - Long-Term Debt to Capital|Current Liabilities to Capital Enovis Corp|ENOV - Company Aggregate Debts|Debt to Book Value Ratio Enovis Inc.|ENOV - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Enovis|Quick Liquidity Indicator enovis.com
- earnings and valuation multiples information:
ENOV - Net Profit
Fundamental valuation:Enovis Inc.
Product sample of Enovis Corporation

Demand for Enovis Corporation (ENOV) orthopedic equipment is limited by the influence of group purchasing organizations, which constrains margin growth. This metric provides a real-time assessment of operating income against current costs, eliminating the time lag associated with standard financial reporting. It measures net cash flow dynamics, identifying phases of profit consolidation or degradation. A stable range of values confirms the issuer's financial stability. By analyzing the company's financial results, an investor can promptly identify drawdown risks.

Key competitors

BSX - Net Financial Result|EW (Edwards Lifesciences) - Net Profit|Net Profit resmed.com|Company Net Income Insulet (PODD)|Company Net Income ZBH (Zimmer Biomet Holdings)|Net Profit COO (CooperVision)|Net Financial Result Align Corp (ALGN)|GMED: Net Income|Profit After Tax TMDX|ATEC: Net Profit|Company Net Income CryoLife (AORT)|IART (Integra) - Net Profit|Company Profit ESTA (Establishment Labs Inc)|Net Income BBNX (Beta Bionics Inc)|IRMD (iradimed.com) - Final Profit|Company Net Income Embecta EMBC|TNDM - Net Income|Axogen Corp - Net Profit|Company Net Income SI-BONE Medical|OFIX: Net Profit|Company Profit BVS|KIDS (OrthoPediatrics Corp) - Net Profit|Treace Medical Concepts Inc (TMCI) - Net Financial Result|Net Profit SRTA|Net Income Carlsmed Medical CARL|Net Profit RXST (RxSight, Inc.)|Net Profit ClearPoint Neuro Inc. CLPT|STXS - Company Net Income|STIM: Company Net Income|SGHT (Sight Sciences, Inc) - Net Income|Orchestra BioMed Inc. - Final Profit|ANIK (Anika Therapeutics Inc.) - Net Profit|Company Net Income inspiremd.com NSPR|Company Net Income Jin Medical International (ZJYL)|vivani.com (VANI) - Annual Net Income|Xtant Medical - Net Income|Net Profit NeuroOne Medical Technologies Corp. NMTC|Modular Med - Net Profit|Net Financial Result myomo.com MYO|Envoy Medical (COCH) - Company Net Income|Profit After Tax VVOS (Vivos Therapeutics Inc.)|Company Net Income enVVeno|Net Income SINTX Technologies (SINT)|Net Profit TNON|LFWD - Company Net Income|Company Net Income Autonomix Medical AMIX|IVF: Company Profit|BBLG: Net Income|Axonics, Inc - Profit After Payment of Taxes|BIOL: Net Profit|Company Net Income Dynatronics (DYNT)|Company Net Income Paragon 28 Inc.|Company Profit INVO (INVO Bio)